<DOC>
	<DOCNO>NCT01194167</DOCNO>
	<brief_summary>This phase II trial study effect drug eltrombopag thrombocytopenia ( low platelet count ) . Eltrombopag approve FDA treatment thrombocytopenia ( low platelet count ) adult insufficient response medication corticosteroids immunoglobulin . Eltrombopag approve FDA ( Food Drug Administration ) treatment thrombocytopenia refractory platelet transfusion study consider investigational .</brief_summary>
	<brief_title>Study Eltrombopag Platelet Refractory Thrombocytopenia</brief_title>
	<detailed_description />
	<mesh_term>Thrombocytopenia</mesh_term>
	<criteria>Laboratory diagnosis platelet refractoriness Diagnosis platelet dependence Adequate liver renal laboratory screen test Patients thrombocytopenia responsive platelet therapy Patients actively receive intravenous immunoglobulin , plasmapheresis cytotoxic medication thrombocytopenia</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>Platelet refractory thrombocytopenia</keyword>
</DOC>